7 Free and Discounted Services You Didn't Know Were Available to Social Security Recipients
Read More:
Find Out:
The good news is that many organizations agree with this. Several programs make food, transportation, and fun all free or cheap for Social Security recipients.
Here are the top seven free or discounted programs that you may not have known were offered to Social Security recipients.
There's something so wonderful about farmers' markets. You get to get outside, mingle with your community, and get fresh, delicious food.
It's not all fruits and vegetables, either. You might find local honey, amazing baked goods, and even a great cup of coffee.
The Senior Farmers' Market Nutrition Program wants America's seniors to get out, move around, and get healthy food. That's why low-income seniors get discount cards that will ensure they can buy from farmers' markets, roadside stands, and local farms at significant discounts.
All you have to do is sign up and get out there.
See Next:
But what if you can't get out there? It happens. It may be that you're not moving around as well as you used to. It might even be a temporary situation, just until you get in better shape.
Fear not.
Meals on Wheels is a program that will make sure you get the good food and nutrition you need while you're more housebound than usual. The organization delivers food to victims of natural disasters and seniors who struggle to leave their homes.
Many social security recipients can't get to the grocery store, or even afford enough groceries to feed themselves as much as they need. Or, you might not be in a position to cook and prepare healthy food. You need to keep your energy and health up to par.
That's where Meals on Wheels comes in. The food is hearty, healthy, and delivered with a smile.
Still, even if you don't have your vehicle, you can still get out. That's thanks to the transportation services available to seniors and Supplemental Security Income (SSI) recipients.
The National Aging and Disability Transportation Center operates in all 50 states and ensures people without transportation, on social services, like Social Security Disability Insurance (SSDI) and SSI, can still get to where they need or want to go.
While many seniors and individuals with disabilities can use public transportation and receive discounts, others are unable to do so. It might be a case of living in a rural area, or you might be in a neighborhood without a close bus line.
In any event, your community should offer a supplemental service like Dial-a-Ride, volunteer transportation, or assisted transportation. Federal grants fund these programs, so they're free to social security recipients.
If you want to get out, you should be able to.
Speaking of getting out, fitness is essential at every age and for every ability. It's good for your body and your brain, and it can even help improve symptoms of many disabilities and aid in healthier aging.
And you can start a new fitness plan at any age. Many seniors realize they need to lift more weights and do more cardio once they retire.
Social Security recipients on Medicare Advantage are eligible for a program called Silver Sneakers. This plan gets you access to thousands of gyms, churches, and other fitness programs across the country.
And you can find a class or program that works for you. You'll find everything from yoga and swimming to Zumba or just plain old gym equipment on the gym floor.
It's a pain to pay your taxes every year. Not only might you have to come up with cash to pay what you owe, but you also have to put your documents in order and pay a preparer.
It's too much.
Well, the federal government agrees with you. Thanks to the VITA program, you may qualify for free tax help. It is particularly aimed at:
People with disabilities
People making less than $65,000
People aged 60 or older
Not only will you get free tax preparation, but you'll be able to trust that these services are reliable as they're certified through the IRS.
Thinking of going back to school? Why not?
Many seniors start a whole new life after retirement, and it can often begin with a few community college courses. Every state in the United States has universities and community colleges that offer free or steeply discounted courses to senior citizens.
You might explore a subject you've always been fascinated by, or you could go back to school to build on your existing education.
One of the greatest advantages of being older is the wisdom you get from life experiences. Building on that wisdom with an academic education can only be a win.
But academic education is not the only kind. The arts are, after all, what keep humans … well … human. And the National Endowment for the Arts (NEA) feels the same way.
That's why the NEA offers free access to thousands of museums across the country for seniors and people with disabilities. And if you don't feel like exploring beauty inside, you can always take advantage of the National Parks' offer to explore one of the many natural beauties around the country.
The National Park Service offers free passes to Social Security recipients, so you can spend your golden years chasing some of the country's most magnificent waterfalls for free.
More From GOBankingRates
How Much Money Is Needed To Be Considered Middle Class in Every State?
This article originally appeared on GOBankingRates.com: 7 Free and Discounted Services You Didn't Know Were Available to Social Security Recipients
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
Funding will advance Strand's pipeline and mission to bring targeted, next-generation mRNA therapies to patients First-in-human solid tumor Phase 1 data from lead program, STX-001, was recently presented at 2025 ASCO Annual Meeting BOSTON, August 07, 2025--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153M Series B funding led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group (the family office of Alex Gorsky), JIC-VGI, LG Technology Ventures, and Gradiant Corporation, with continued participation from existing investors including FPV Ventures, Playground Global, Eli Lilly and Company, ANRI, and Potentum. To date, Strand has raised over $250M. As part of the financing, Ala Alenazi, Ph.D., of Kinnevik, will join the company's Board of Directors. The funding will advance Strand's pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironment. The company recently announced promising initial Phase 1 clinical data for patients with advanced solid tumors at the 2025 ASCO annual meeting, noting multiple RECIST responses (including cases of complete response and complete metabolic response), multiple cases of prolonged disease stabilization, and a favorable safety profile in treatment-resistant patients. Earlier this year, Strand also presented preclinical data for STX-003, a world-first systemically administrable mRNA therapy with tumor targeting that is programmed to avoid off-target payload delivery (including liver avoidance), showing the first glimpse into the massive potential of their programmable mRNA genetic circuits. Data presented at the 2025 AACR and ASGCT annual meetings demonstrated the candidate's potential to target expression of IL-12 to tumors following systemic administration of the LNP-mRNA drug, creating an effective anti-tumor therapy that was well tolerated. IL-12 is a potent pro-inflammatory cytokine primarily produced by antigen-presenting cells such as macrophages and dendritic cells. IL-12 holds significant promise in cancer immunotherapy due to its robust immunostimulatory effects. STX-001 encodes IL-12 which Strand has designed so that it can reprogram the tumor microenvironment and stimulate a systemic anti-tumor immune response. Unlike traditional mRNA therapies, Strand's approach uses self-replicating mRNA, ensuring localized and durable therapeutic activity. "We believe programmable RNA is the next frontier in therapeutics, and Strand has built the leading platform to unlock it," said Christian Scherrer, Senior Investment Director and Head of Health and Bio at Kinnevik. "Their early clinical data is outstanding, and the systemic delivery capability has the potential to reshape how we treat disease, starting with cancer, with more disease targets on the horizon. We look forward to partnering with founders Jake and Tasuku and the entire team as they move into this next phase of growth." "With support from our investors, we're advancing our vision of developing safe, effective, and accessible therapies through programmable genetic medicines, especially for those patients with few treatment options," said Jake Becraft, PhD, CEO and Co-founder of Strand Therapeutics. "Our initial STX-001 Phase 1 data provides early and strong clinical validation of our platform's capabilities. We have observed systemic immune activation and anti-tumor responses, including responses in non-injected lesions, across multiple tumor types. Now is an exciting period of expansion for our existing clinical work, as well as the exciting breakthrough assets in our pipeline, all with the potential to transform the treatment of cancer and other serious diseases." Strand's proprietary platform for programmable and potent mRNA therapeutics is the first of its kind. Its therapies combine best-in-class engineered next-generation mRNA modalities, such as self-replicating mRNA and circular RNA, with genetically programmed logic circuits, allowing for precise, controlled therapeutic payload delivery directly into the cells/tissues themselves. The novel approach brings the potential to effectively treat cancer and other deadly chronic diseases through its targeted therapies that are scalable, accessible, and expand the treatment landscape for patients desperately in need. About STX-001 STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period of time, directly administered to tumors in order to promote immune modulation and antitumor activity. The company received IND clearance from the U.S. Food and Drug Administration (FDA) in December 2023 to initiate a Phase 1/2 clinical trial for STX-001, announced its first patient dosed just before the 2024 ASCO Annual Meeting, and presented the first data of the trial at the 2025 ASCO Annual Meeting. Additional details can be found at using identifier: NCT06249048. About Strand Therapeutics Strand Therapeutics is leading the next generation of programmable mRNA therapies: where synthetic biology meets programmable biology to unlock the full potential of gene regulation and delivery inside the body. Unlike traditional mRNA technologies, Strand's platform programs RNA to think, enabling logic-controlled expression, precision delivery, and unprecedented control over therapeutic outcomes. Born out of MIT and led by world-class synthetic biologists, Strand is building the infrastructure to create medicines that respond to disease signals in real-time. With its computationally-driven design engine, self-amplifying/circular RNA modalities, and mRNA-only genetic circuits, the company is pioneering a new therapeutic modality poised to disrupt immuno-oncology, cell therapy, autoimmune diseases, and beyond. Strand's lead pipeline program, STX-001, is already in the clinic showing unprecedented response rates in late stage "salvage" cancer patients, with multiple patients showing RECIST responses. Strand's modular platform opens a broad horizon of partnership and licensing opportunities. Strand isn't just another mRNA company: it's the operating system for the programmable medicines of tomorrow. Follow us on LinkedIn and on X at @strandtx. View source version on Contacts Media contacts:Karen Sharmaksharma@ Shannia Coleyscoley@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
Launch supported by strong assay performance in first milestone readout of the landmark EXPAND clinical trial AUSTIN, Texas, August 07, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test (NIPT) for inherited conditions. When a pregnant patient is identified as a carrier of a recessive single-gene condition, medical guidelines recommend partner testing in order to determine the risk for the baby to be affected by the condition1; however, in some cases the biological father is unavailable for testing. The Fetal Focus test was designed to address this unmet need. Now if a pregnant patient tests positive with Natera's Horizon™ carrier screen for one of the five most commonly tested genes, and if the father is unavailable for testing, Fetal Focus can screen the fetus directly for that gene by simply analyzing a sample of the mother's blood. Fetal Focus is validated for the analysis of five genes: CFTR (cystic fibrosis), SMN1 (spinal muscular atrophy), HBA1 and HBA2 (alpha-thalassemia), and HBB (beta-hemoglobinopathies, including sickle cell disease). The launch is supported by data from EXPAND, a large, prospective, blinded clinical trial. The study, which was initiated in 2023, has enrolled approximately 1,300 participants to date, reflecting a diverse, multi-ethnic population from leading academic medical centers and maternal fetal medicine clinics. EXPAND is designed to be the defining clinical trial in the category, with all outcomes, including both positive and negative results, confirmed by genetic truth using prenatal or postnatal diagnostic testing. In its first milestone readout (n=101) from EXPAND, the Fetal Focus test demonstrated 91% sensitivity and successfully identified 5/5 fetuses affected by homozygous variants.2,3 Homozygous cases, where the fetus inherits the same condition-causing variant from both parents, are especially challenging to detect. Fetal Focus uses Natera's proprietary LinkedSNP™ technology to improve detection of these cases across diverse populations. "Having access to a noninvasive option like Fetal Focus can provide critical information to support decision-making during pregnancy, especially in situations where partner testing isn't possible," said John Williams, M.D., chief principal investigator for EXPAND and director of reproductive genetics at Cedars-Sinai. "Fetal Focus adds another important offering within our comprehensive reproductive health portfolio – furthering our commitment to launching products that address clinical gaps in care and are supported by rigorous clinical validation," said Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women's health at Natera. "The EXPAND study has been underway for several years, and we're pleased to release this first milestone readout." References ACOG Committee Opinion #690, Mar 2017. Internal data on file. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results. EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). Accessed July 2025. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio
Yahoo
a minute ago
- Yahoo
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call InformationTo participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: A replay of the webcast will be available on the Celcuity website following the live event. About Celcuity Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about Celcuity's active clinical trials can be found at Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at Follow us on LinkedIn and X. View source version of release on Contacts: Celcuity Inc. Brian Sullivan, bsullivan@ Vicky Hahne, vhahne@ (763) 392-0123 ICR HealthcarePatti Bank, (415) 513-1284Sign in to access your portfolio
